BCG029 / Biocytogen - LARVOL DELTA

BCG029: An ADAM9-Targeting ADC Featuring a Novel Topoisomerase I Inhibitor Payload Demonstrated Potent Efficacy in PDX Models (AACR 2026) - "Ongoing in vivo studies are continuing to evaluate the performance of BCG029.These findings underscore the therapeutic potential of BCG029 in targeting solid tumors that express ADAM9. By targeting ADAM9 specifically, BCG029 could provide a safer and more effective treatment option for patients with ADAM9-expressing tumors."

ADC • Clinical • Colorectal Cancer • Oncology • Solid Tumor • ADAM9 • TOP1

An ADAM9-targeting ADC featuring a novel topoisomerase I inhibitor payload demonstrated potent efficacy in PDX models (AACR 2026) - "Ongoing in vivo studies are continuing to evaluate the performance of BCG029.These findings underscore the therapeutic potential of BCG029 in targeting solid tumors that express ADAM9. By targeting ADAM9 specifically, BCG029 could provide a safer and more effective treatment option for patients with ADAM9-expressing tumors."

ADC • Clinical • Colorectal Cancer • Oncology • Solid Tumor • ADAM9 • TOP1